NASDAQ:PODD - Insulet Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $266.43
  • Forecasted Upside: -5.67 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$282.45
▲ +0.85 (0.30%)
1 month | 3 months | 12 months
Get New Insulet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PODD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PODD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$266.43
▼ -5.67% Downside Potential
This price target is based on 15 analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $266.43, with a high forecast of $300.00 and a low forecast of $230.00. The average price target represents a -5.67% upside from the last price of $282.45.

Hold

The current consensus among 15 contributing investment analysts is to hold stock in Insulet. This rating has held steady since March 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 1 sell ratings
12/21/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 1 sell ratings
3/20/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 1 sell ratings
6/18/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 10 hold ratings
  • 1 sell ratings
9/16/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 1 sell ratings
12/15/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 11 hold ratings
  • 1 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/14/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings
6/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2021BarclaysInitiated CoverageOverweight$300.00Low
i
5/7/2021Raymond JamesLower Price TargetOutperform$296.00 ➝ $285.00High
i
5/7/2021SVB LeerinkLower Price TargetOutperform$320.00 ➝ $300.00High
i
Rating by D. Antalffy at SVB Leerink LLC
5/7/2021Piper SandlerLower Price TargetNeutral$260.00 ➝ $250.00High
i
5/7/2021BTIG ResearchReiterated RatingHoldHigh
i
4/1/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$275.00 ➝ $320.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
3/19/2021Canaccord GenuityUpgradeHold ➝ Buy$280.00High
i
3/2/2021SVB LeerinkBoost Price TargetMarket Perform$255.00 ➝ $275.00Low
i
2/25/2021OppenheimerBoost Price TargetMarket Perform$235.00 ➝ $277.00High
i
2/24/2021SVB LeerinkReiterated RatingMarket Perform$255.00 ➝ $275.00High
i
2/24/2021Raymond JamesBoost Price TargetOutperform$282.00 ➝ $296.00Low
i
2/1/2021BTIG ResearchReiterated RatingHoldLow
i
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$260.00Medium
i
1/15/2021Wells Fargo & CompanyReiterated RatingBuyMedium
i
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$255.00 ➝ $268.00Medium
i
12/16/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngradeBuy ➝ Neutral$255.00 ➝ $268.00Medium
i
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$246.00 ➝ $276.00Low
i
11/5/2020Canaccord GenuityBoost Price TargetHold$210.00 ➝ $240.00High
i
11/5/2020UBS GroupBoost Price TargetNeutral$230.00 ➝ $245.00Medium
i
11/5/2020Wells Fargo & CompanyBoost Price TargetOverweight$250.00 ➝ $266.00High
i
11/5/2020Raymond JamesBoost Price TargetOutperform$249.00 ➝ $250.00High
i
11/5/2020Morgan StanleyBoost Price TargetEqual Weight$232.00 ➝ $246.00High
i
10/12/2020SVB LeerinkBoost Price TargetMarket Perform$240.00 ➝ $255.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
8/7/2020Morgan StanleyBoost Price TargetEqual Weight$222.00 ➝ $232.00High
i
8/7/2020OppenheimerReiterated RatingHold$235.00Medium
i
8/7/2020StephensBoost Price TargetPositive ➝ Equal Weight$165.00 ➝ $230.00Medium
i
8/7/2020SVB LeerinkBoost Price TargetMarket Perform$215.00 ➝ $240.00Medium
i
Rating by D. Antalffy at SVB Leerink LLC
8/7/2020Raymond JamesBoost Price TargetOutperform$200.00 ➝ $249.00Medium
i
8/7/2020CitigroupBoost Price TargetBuy$200.00 ➝ $255.00Medium
i
8/6/2020Piper SandlerReiterated RatingOverweight$235.00 ➝ $260.00Medium
i
Rating by Matthew O'Brien at Piper Sandler
7/28/2020Wells Fargo & CompanyInitiated CoverageOverweight$231.00High
i
7/7/2020CowenBoost Price TargetPositive ➝ Outperform$220.00 ➝ $230.00Low
i
Rating by Ryan Blicker at Cowen Inc
6/9/2020Raymond JamesLower Price TargetOutperform$220.00 ➝ $200.00Low
i
5/8/2020CfraBoost Price TargetSell$162.00 ➝ $179.00Low
i
5/8/2020UBS GroupBoost Price TargetNeutral$195.00 ➝ $213.00High
i
5/8/2020Stifel NicolausBoost Price TargetHold$161.00 ➝ $195.00High
i
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$200.00 ➝ $235.00High
i
5/8/2020Robert W. BairdBoost Price Target$189.00 ➝ $242.00High
i
5/8/2020Morgan StanleyBoost Price TargetEqual Weight$186.00 ➝ $222.00Medium
i
5/8/2020SVB LeerinkBoost Price TargetMarket Perform$200.00 ➝ $230.00High
i
Rating by D. Antalffy at SVB Leerink LLC
5/8/2020CitigroupBoost Price TargetBuy$206.00 ➝ $250.00High
i
4/27/2020Raymond JamesBoost Price TargetOutperform$205.00 ➝ $220.00Medium
i
4/24/2020SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by D. Antalffy at SVB Leerink LLC
4/3/2020Bank of AmericaInitiated CoverageNeutral$200.00Medium
i
3/31/2020Berenberg BankDowngradeBuy ➝ HoldHigh
i
3/27/2020Morgan StanleyBoost Price TargetEqual Weight$181.00 ➝ $186.00Low
i
3/27/2020CitigroupLower Price TargetBuy$220.00 ➝ $206.00Medium
i
3/4/2020CitigroupInitiated CoverageBuy$220.00Low
i
2/26/2020Piper SandlerReiterated RatingBuy$200.00High
i
Rating by Matthew O'Brien at Piper Sandler
2/26/2020CowenReiterated RatingBuyHigh
i
Rating by Ryan Blicker at Cowen Inc
2/26/2020CfraLower Price TargetSell$163.00 ➝ $162.00Low
i
2/26/2020Robert W. BairdLower Price TargetOutperform$225.00 ➝ $215.00High
i
2/26/2020BTIG ResearchReiterated RatingHoldHigh
i
2/26/2020Raymond JamesLower Price TargetOutperform$213.00 ➝ $205.00High
i
2/6/2020Raymond JamesBoost Price TargetOutperform$158.00 ➝ $213.00Medium
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$170.00 ➝ $200.00Medium
i
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$148.00 ➝ $181.00Low
i
12/10/2019CfraInitiated CoverageSell$163.00Medium
i
12/9/2019Canaccord GenuityBoost Price TargetHold$150.00 ➝ $165.00Low
i
Rating by Kyle Rose at Canaccord Genuity
11/18/2019Piper Jaffray CompaniesBoost Price TargetOverweight$170.00 ➝ $200.00Low
i
Rating by JP McKim at Piper Jaffray Companies
11/6/2019Raymond JamesBoost Price TargetOutperform$135.00 ➝ $158.00High
i
11/6/2019Piper Jaffray CompaniesReiterated RatingOverweight$160.00 ➝ $170.00High
i
Rating by JP McKim at Piper Jaffray Companies
10/22/2019Stifel NicolausInitiated CoverageHold$163.00High
i
10/21/2019CowenSet Price TargetBuy$165.00Medium
i
Rating by Ryan Blicker at Cowen Inc
10/18/2019Canaccord GenuityDowngradeBuy ➝ Hold$135.00 ➝ $145.00Medium
i
10/14/2019BTIG ResearchDowngradeBuy ➝ NeutralMedium
i
10/4/2019UBS GroupDowngradeBuy ➝ Neutral$155.00 ➝ $160.00Low
i
10/3/2019GuggenheimDowngradeBuy ➝ NeutralMedium
i
9/24/2019SVB LeerinkBoost Price TargetOutperform$160.00 ➝ $185.00High
i
Rating by D. Antalffy at SVB Leerink LLC
9/23/2019Piper Jaffray CompaniesReiterated RatingBuyLow
i
Rating by JP McKim at Piper Jaffray Companies
8/6/2019Morgan StanleyBoost Price TargetEqual Weight$127.00 ➝ $135.00High
i
8/6/2019BTIG ResearchBoost Price TargetBuy$140.00High
i
8/6/2019BMO Capital MarketsBoost Price TargetOutperform$130.00 ➝ $150.00High
i
8/6/2019Jefferies Financial GroupBoost Price TargetBuy$105.00 ➝ $140.00High
i
8/6/2019Raymond JamesBoost Price TargetOutperform$125.00 ➝ $135.00High
i
8/6/2019GuggenheimBoost Price TargetBuy ➝ Positive$100.00 ➝ $145.00High
i
8/6/2019Canaccord GenuityBoost Price TargetBuy$110.00 ➝ $135.00High
i
8/6/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$120.00 ➝ $155.00High
i
8/6/2019Piper Jaffray CompaniesBoost Price TargetOverweight$130.00 ➝ $160.00High
i
7/16/2019Morgan StanleyBoost Price TargetEqual Weight$98.00 ➝ $127.00Low
i
7/10/2019SVB LeerinkReiterated RatingOutperformLow
i
Rating by D. Antalffy at SVB Leerink LLC
6/28/2019Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Positive$110.00 ➝ $130.00High
i
6/27/2019JPMorgan Chase & Co.Boost Price TargetNeutral$90.00 ➝ $120.00Low
i
6/13/2019UBS GroupBoost Price TargetBuy$110.00 ➝ $130.00Low
i
6/10/2019Northland SecuritiesDowngradeOutperform ➝ Market Perform$100.00Low
i
5/6/2019Canaccord GenuityReiterated RatingBuy$100.00 ➝ $110.00High
i
5/6/2019BTIG ResearchUpgradeNeutral ➝ Buy$115.00High
i
2/26/2019OppenheimerSet Price TargetHold$100.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/26/2019Northland SecuritiesReiterated RatingBuy$100.00High
i
2/19/2019Canaccord GenuityBoost Price TargetBuy$90.00 ➝ $100.00Medium
i
1/3/2019SVB LeerinkReiterated RatingOutperform$110.00 ➝ $100.00Medium
i
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$105.00 ➝ $90.00High
i
11/27/2018UBS GroupInitiated CoverageBuy$105.00Medium
i
11/2/2018OppenheimerSet Price TargetHold$100.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$96.00 ➝ $105.00Medium
i
9/11/2018SVB LeerinkReiterated RatingOutperform$130.00Medium
i
8/3/2018Jefferies Financial GroupReiterated RatingBuy$97.00Low
i
8/3/2018OppenheimerSet Price TargetHold$96.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/10/2018BMO Capital MarketsBoost Price TargetTop Pick$115.00Medium
i
6/4/2018Piper Jaffray CompaniesBoost Price TargetOverweight$106.00Low
i
6/1/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$87.00 ➝ $96.00Low
i
5/23/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$96.00 ➝ $100.00Low
i
5/4/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$90.00 ➝ $100.00High
i
5/4/2018Northland SecuritiesReiterated RatingBuy$100.00Low
i
5/4/2018OppenheimerSet Price TargetHold$90.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/3/2018Piper Jaffray CompaniesBoost Price TargetOverweight$88.00 ➝ $90.00High
i
5/2/2018Canaccord GenuityReiterated RatingBuy$90.00Medium
i
4/20/2018Berenberg BankInitiated CoverageBuy$100.00Medium
i
4/3/2018GuggenheimInitiated CoverageBuy$105.00Low
i
3/5/2018BMO Capital MarketsInitiated CoverageOutperform$90.00High
i
2/23/2018Jefferies Financial GroupReiterated RatingBuy$90.00Low
i
2/23/2018Canaccord GenuityBoost Price TargetNeutral$78.00 ➝ $88.00Low
i
2/22/2018CowenReiterated RatingOutperform ➝ Outperform$80.00 ➝ $90.00Medium
i
2/22/2018OppenheimerSet Price TargetHold$82.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/22/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$76.00 ➝ $87.00High
i
2/22/2018StephensReiterated RatingEqual Weight ➝ Equal Weight$60.00 ➝ $81.00High
i
2/22/2018BarclaysReiterated RatingOverweight ➝ Overweight$85.00 ➝ $90.00High
i
1/8/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$80.00High
i
1/8/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
i
12/13/2017BarclaysReiterated RatingBuy$78.00Low
i
11/20/2017BarclaysBoost Price TargetOverweight$70.00 ➝ $75.00N/A
i
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$55.00 ➝ $63.00N/A
i
11/3/2017Jefferies Financial GroupBoost Price TargetBuy$58.00 ➝ $67.00N/A
i
11/3/2017Robert W. BairdBoost Price TargetOutperform$65.00 ➝ $72.00N/A
i
Rating by Jeff Johnson at Robert W. Baird
11/1/2017Canaccord GenuityUpgradeHold ➝ Buy$50.00 ➝ $65.00N/A
i
10/13/2017Robert W. BairdSet Price TargetBuy$65.00N/A
i
10/12/2017SVB LeerinkReiterated RatingOutperform$65.00 ➝ $74.00N/A
i
10/10/2017WedbushReiterated RatingBuy$60.00 ➝ $65.00N/A
i
9/27/2017Canaccord GenuityReiterated RatingHold$50.00Medium
i
9/15/2017BarclaysInitiated CoverageOverweight ➝ Overweight$65.00Low
i
8/9/2017Jefferies Financial GroupReiterated RatingBuy$48.00 ➝ $58.00Low
i
8/4/2017OppenheimerSet Price TargetHold$55.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/4/2017Northland SecuritiesReiterated RatingBuyLow
i
Rating by Suraj Kalia at Northland Securities
8/4/2017CowenReiterated RatingOutperform$52.00 ➝ $63.00High
i
7/22/2017OppenheimerReiterated RatingHoldHigh
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/17/2017BTIG ResearchDowngradeBuy ➝ NeutralMedium
i
7/14/2017CowenReiterated RatingBuy$52.00Medium
i
7/14/2017Jefferies Financial GroupReiterated RatingBuy$48.00Low
i
7/11/2017Canaccord GenuityReiterated RatingHold$42.00 ➝ $50.00Low
i
Rating by Kyle Rose at Canaccord Genuity
6/16/2017Jefferies Financial GroupReiterated RatingBuyLow
i
5/26/2017Canaccord GenuityReiterated RatingHold$42.00Low
i
Rating by Kyle Rose at Canaccord Genuity
5/25/2017William BlairReiterated RatingOutperform ➝ OutperformLow
i
Rating by M. Kaczor at William Blair
5/22/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$47.00Low
i
5/14/2017B. RileyReiterated RatingNeutral$44.00Low
i
5/10/2017Jefferies Financial GroupLower Price TargetBuy$53.00 ➝ $48.00Medium
i
5/10/2017BTIG ResearchUpgradeNeutral ➝ Buy$47.00Medium
i
5/9/2017B. RileyReiterated RatingNeutral$44.00High
i
5/9/2017OppenheimerSet Price TargetHold$46.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/9/2017Northland SecuritiesReiterated RatingBuy$50.00High
i
4/13/2017Jefferies Financial GroupReiterated RatingBuy$53.00Low
i
3/6/2017B. RileyReiterated RatingNeutral$44.00N/A
i
3/6/2017BTIG ResearchDowngradeBuy ➝ NeutralN/A
i
3/1/2017B. RileyReiterated RatingNeutral$44.00N/A
i
2/28/2017OppenheimerSet Price TargetHold$46.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/28/2017Jefferies Financial GroupBoost Price TargetBuy$45.00 ➝ $53.00N/A
i
2/28/2017WedbushBoost Price TargetOutperform ➝ Outperform$48.00 ➝ $50.00N/A
i
2/27/2017Feltl & Co.DowngradeBuy ➝ HoldN/A
i
Rating by B. Haynor at Feltl & Co.
2/13/2017Canaccord GenuityReiterated RatingHold$39.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
1/23/2017Canaccord GenuitySet Price TargetHold$39.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
1/8/2017BTIG ResearchReiterated RatingBuy$42.00N/A
i
Rating by Sean Lavin at BTIG Research
1/6/2017Robert W. BairdUpgradeNeutral ➝ Outperform$39.00 ➝ $47.00N/A
i
11/17/2016JPMorgan Chase & Co.Reiterated RatingHold$38.00N/A
i
11/17/2016WedbushReiterated RatingOutperform$48.00N/A
i
11/9/2016B. RileyReiterated RatingNeutral$40.00N/A
i
11/7/2016SVB LeerinkReiterated RatingOutperform$55.00 ➝ $50.00N/A
i
11/6/2016Canaccord GenuitySet Price TargetHold$39.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
11/4/2016B. RileyReiterated RatingNeutral$40.00N/A
i
11/4/2016JPMorgan Chase & Co.Reiterated RatingHold$38.00N/A
i
11/4/2016BTIG ResearchUpgradeNeutral ➝ Buy$42.00N/A
i
Rating by Sean Lavin at BTIG Research
10/2/2016B. RileyInitiated CoverageNeutral$46.00N/A
i
9/26/2016B. RileyInitiated CoverageNeutral$46.00N/A
i
Rating by G. Chodaczek at B. Riley
8/17/2016JPMorgan Chase & Co.Reiterated RatingHold$38.00N/A
i
8/16/2016Piper Jaffray CompaniesReiterated RatingOverweight$52.00N/A
i
Rating by Brooks West at Piper Jaffray Companies
8/5/2016Canaccord GenuityReiterated RatingHold$36.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
8/4/2016SVB LeerinkReiterated RatingOutperform$40.00 ➝ $50.00N/A
i
8/4/2016Piper Jaffray CompaniesReiterated RatingOverweight$41.00 ➝ $46.00N/A
i
Rating by Brooks West at Piper Jaffray Companies
8/4/2016Jefferies Financial GroupBoost Price TargetBuy$41.00 ➝ $45.00N/A
i
8/4/2016WedbushBoost Price TargetOutperform$44.00 ➝ $48.00N/A
i
7/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$41.00N/A
i
Rating by Brooks West at Piper Jaffray Companies
7/20/2016WedbushReiterated RatingOutperform$44.00N/A
i
7/12/2016BTIG ResearchInitiated CoverageNeutralN/A
i
6/22/2016WedbushReiterated RatingOutperform$44.00N/A
i
Rating by Tao Levy at Wedbush
6/15/2016WedbushReiterated RatingOutperform$44.00N/A
i
Rating by Tao Levy at Wedbush
(Data available from 6/14/2016 forward)
Insulet logo
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Read More

Today's Range

Now: $282.45
$279.00
$282.61

50 Day Range

MA: $269.65
$225.52
$304.06

52 Week Range

Now: $282.45
$175.35
$306.46

Volume

518,800 shs

Average Volume

523,141 shs

Market Capitalization

$18.72 billion

P/E Ratio

2,172.69

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Insulet?

The following Wall Street sell-side analysts have issued reports on Insulet in the last year: Barclays PLC, BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Smith Barney Citigroup, Stephens, SVB Leerink LLC, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for PODD.

What is the current price target for Insulet?

14 Wall Street analysts have set twelve-month price targets for Insulet in the last year. Their average twelve-month price target is $266.43, suggesting a possible downside of 5.7%. Barclays PLC has the highest price target set, predicting PODD will reach $300.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $230.00 for Insulet in the next year.
View the latest price targets for PODD.

What is the current consensus analyst rating for Insulet?

Insulet currently has 8 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PODD, but not buy more shares or sell existing shares.
View the latest ratings for PODD.

What other companies compete with Insulet?

How do I contact Insulet's investor relations team?

Insulet's physical mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier's listed phone number is 978-600-7000 and its investor relations email address is [email protected] The official website for Insulet is www.insulet.com.